ACRO to Help Lead Clinical Trials Transformation Initiative
ACRO to collaborate with key stakeholders on efforts to enhance the clinical research enterprise.
Washington, DC-May 6, 2008-The Association of Clinical Research Organizations (ACRO; www.acrohealth.org), which represents the clinical outsourcing industry to regulators, biopharmaceutical clients, policymakers, and the public in the United States and worldwide, today announced its leadership role in the recently formed Clinical Trial Transformation Initiative (CTTI). The goal of the CTTI is to modernize the mechanics of clinical trials and to increase their efficiency and productivity.
The CTTI was established by the U.S. Food and Drug Administration (FDA) in collaboration with Duke University as part of the FDA’s Critical Path Initiative. Alberto Grignolo, corporate vice president and general manager of Parexel Consulting, a business unit of Parexel International, will represent the association on the CTTI Executive Board, which is comprised of experts from the FDA, National Institutes of Health (NIH), academia, biopharmaceutical companies, CROs, and other organizations.
“ACRO is excited to be a part of this important effort to further enhance the clinical trial process,” said ACRO Executive Director Doug Peddicord.“We are pleased to have an industry leader like Dr. Grignolo participating on behalf of the association to share the CRO perspective and the expertise of our members with the consortium.”
“CTTI has an important charge as it looks to establish models for clinical trial innovation in areas such as study design, operating procedures, and metrics for evaluation,” said Dr. Grignolo.“I look forward to representing the CRO industry and working with the wide range of stakeholders involved to help make this initiative successful for all who participate in the clinical trial enterprise, including study participants, investigators, regulators, sponsors, and CROs.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
